Vaccination is a major element of public-health policies in all of the world’s countries. In developing countries, the main goal is usually to prevent epidemics, whereas in mature countries it is more about maintaining a high level of protection for all. Vaccines are not just for children; adults too benefit from vaccination. For example, influenza vaccination in adults staves off a week of fever, headaches and muscle pain in individuals, stops the disease from affecting families and local economies, and prevents the propagation of the virus in the general population, thus creating a “cocoon” around its most fragile members, the elderly and infants.

**A recognized world leader**
With its wide range of products, ability to innovate and industrial expertise, Sanofi Pasteur is today a world leader in vaccines. This position makes the company a recognized partner not only for governments and national health authorities but also for the World Health Organization (WHO) and the major international funds involved in vaccination campaigns in developing countries. The company increased 5.7% in 2012, thanks in particular to strong performance in vaccines for influenza (Vaxigrip®), meningitis (Menactra®) and poliomyelitis (Imovax® Polio, notably in Japan).

**A MAJOR ADVANCE AGAINST POLIO IN JAPAN**
Japan has been routinely vaccinating against polio since 1960 with an oral, live attenuated vaccine. However, in 2012, the country decided to authorize Sanofi Pasteur’s inactivated polio vaccine, Imovax® Polio. Japan’s authorization of this vaccine will greatly advance its use for the prevention of polio. A growing number of polio-free countries are currently integrating inactivated polio vaccine in their national immunization programs.

Any information provided on cited products is in no way intended to encourage their use.
MORE THAN 3 MILLION LIVES SAVED EACH YEAR THROUGH IMMUNIZATION
Source WHO.

20 OF THE 26 VACCINE-PREVENTABLE DISEASES ARE COVERED BY THE SANOFI PASTEUR RANGE OF PRODUCTS

Vaccines protect life.
To avoid the health, social and economic consequences of vaccine-preventable diseases, Sanofi contributes to the prevention of epidemics and maintains a high level of protection thanks to its innovative vaccines.
Currently there are close to 3 billion people living in dengue-endemic regions. Although tropical and subtropical in nature, the virus has been detected in Europe, South America and the United States. In 2012, Sanofi Pasteur joined with the CNES, France’s national space technologies center, for a pilot project focused on mapping zones threatened by dengue. The project’s goal is to improve epidemic prediction and thus allow for better preparation. Developed jointly by the CNES and its various partners, the concept of “tele-epidemiology” employs new satellite imaging technologies to develop provisional maps for environmental risks that favor the emergence of certain pathogenic agents. The innovative nature of the project is all the stronger in that it calls upon many scientific disciplines, such as epidemiology, entomology, remote sensing technologies and statistics applied to tele-epidemiology and meteorology.

**Towards a dengue vaccine**
Sanofi Pasteur develops innovative solutions for people everywhere. We do this by responding to unmet needs, improving vaccine combinations and adapting our vaccines to different population profiles. The year 2012 was thus notable in particular for a decisive advance in the development of a vaccine to prevent dengue. This disease, often called dengue fever, is a major issue in public health. Sanofi Pasteur has had dengue in its sights since 1992. The development of a vaccine became a priority for the company in 2007, when a candidate vaccine was identified. In July 2012, the results of the first efficacy trial for the vaccine confirmed its excellent tolerance profile and its ability to protect against three of the four viruses circulating in Thailand, where the trial was performed. Today, large Phase III trials are underway in 10 Asian and Latin American countries.
Innovating for the world’s populations
Sanofi Pasteur’s ability to innovate can be seen via the company’s expertise in pediatric combination vaccines. These latter offer an advantage in comfort for babies and infants because they vaccinate against several diseases with a single injection. In 2012, the European Medicines Agency issued a favorable scientific opinion for Hexaxim®, Sanofi Pasteur’s 6-in-1 pediatric vaccine, thus clearing the way for the vaccine’s approval on international, non-European markets. Sanofi Pasteur has also developed an innovative diversification strategy for flu vaccines. In the United States, where universal vaccination is recommended, the company delivered 60 million doses of seasonal influenza vaccine in 2012.

The 6-in-1 pediatric vaccine is the only liquid hexavalent ready-to-use vaccine available. It offers a clear advantage for simplifying childhood immunization schedules.

To better respond to the specificities of different age groups, the vaccine was provided in two forms: an intradermal pediatric version (Fluzone® Intradermal) and a highly concentrated version (Fluzone® High Dose) to counter the effects of immunosenescence in elderly populations.

A responsible industrial investment
Sanofi Pasteur produces more than a billion vaccine doses yearly. To respond to ever-increasing demands, the company reinvests each year an important part of its revenue into production capabilities. Significant constraints are present in the production of vaccines: cycles are long and the deployment of a new production unit takes four to six years. Sanofi Pasteur is currently developing a vaccine against dengue, a disease for which there is no treatment currently available. As early as 2009, to ensure that the vaccine will be available to exposed populations, the company chose to invest €300 million in an industrial site close to Lyon, France, to assure its production. This choice represents the single largest investment ever made within the Sanofi Pasteur industrial network.